Simultaneous elimination of DNA damage-induced defense mechanisms, through transient pharmacologic inhibition of PP2A, is proposed as a new method for enhancing the efficacy of non-specific cancer chemotherapy regimens against a broad spectrum of low growth fraction tumors, such as PHEOs, that are commonly resistant to cytotoxic drugs. This evidence concerns the gene PTPA and cancer.